{"id":3387,"date":"2024-05-29T09:15:24","date_gmt":"2024-05-29T01:15:24","guid":{"rendered":"https:\/\/flcube.com\/?p=3387"},"modified":"2024-10-20T17:58:49","modified_gmt":"2024-10-20T09:58:49","slug":"3sbio-secures-license-for-semaglutide-biosimilar-from-hybio-pharmaceutical","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=3387","title":{"rendered":"3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical"},"content":{"rendered":"\n

3SBio Inc. (HKG: 1530<\/a>), a biopharmaceutical company based in China, has announced a licensing agreement with fellow Chinese firm Hybio Pharmaceutical Co., Ltd (SHE: 300199<\/a>) for the development of a semaglutide biosimilar. Under this agreement, 3SBio will gain access to Hybio’s preclinical technical results for the drug and will be responsible for clinical research and registration application work. This will enable 3SBio to become the marketing authorization holder (MAH) for the semaglutide product, indicated for weight loss, in a specific region, granting them exclusive marketing rights and commercialization responsibilities. Additionally, 3SBio will entrust Hybio with the exclusive production and supply of the semaglutide product for weight loss indication.<\/p>\n\n\n\n

3SBio will make a milestone payment of RMB 270 million to Hybio, which includes an upfront payment of RMB 45 million for the pre-clinical technological achievements, along with double-digit sales commission based on future performance.<\/p>\n\n\n\n

Semaglutide, originally developed by Novo Nordisk, is a GLP-1 receptor agonist used for weight management in specific patients, as well as for glycemic control in type 2 diabetes and reduction of major cardiovascular events risk. Other Chinese companies like Livzon Pharma, Huadong Medicine, and Sinopep Biopharma are also developing their own biosimilar versions of this drug.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced a licensing agreement…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[116,43,1061,114,287,457,148,86,1106],"class_list":["post-3387","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-3sbio","tag-biosimilars","tag-hkg-1530","tag-huadong-medicine","tag-hybio-pharmaceutical","tag-livzon-pharmaceutical","tag-novo-nordisk","tag-obesity","tag-she-300199"],"yoast_head":"\n3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced a licensing agreement with fellow Chinese firm Hybio Pharmaceutical Co., Ltd (SHE: 300199) for the development of a semaglutide biosimilar. Under this agreement, 3SBio will gain access to Hybio's preclinical technical results for the drug and will be responsible for clinical research and registration application work. This will enable 3SBio to become the marketing authorization holder (MAH) for the semaglutide product, indicated for weight loss, in a specific region, granting them exclusive marketing rights and commercialization responsibilities. Additionally, 3SBio will entrust Hybio with the exclusive production and supply of the semaglutide product for weight loss indication.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=3387\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=3387\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-29T01:15:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-20T09:58:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3387#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3387\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical\",\"datePublished\":\"2024-05-29T01:15:24+00:00\",\"dateModified\":\"2024-10-20T09:58:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3387\"},\"wordCount\":207,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"3SBio\",\"Biosimilars\",\"HKG: 1530\",\"Huadong Medicine\",\"Hybio Pharmaceutical\",\"Livzon Pharmaceutical\",\"Novo Nordisk\",\"Obesity\",\"SHE: 300199\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=3387#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3387\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=3387\",\"name\":\"3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-05-29T01:15:24+00:00\",\"dateModified\":\"2024-10-20T09:58:49+00:00\",\"description\":\"3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced a licensing agreement with fellow Chinese firm Hybio Pharmaceutical Co., Ltd (SHE: 300199) for the development of a semaglutide biosimilar. Under this agreement, 3SBio will gain access to Hybio's preclinical technical results for the drug and will be responsible for clinical research and registration application work. This will enable 3SBio to become the marketing authorization holder (MAH) for the semaglutide product, indicated for weight loss, in a specific region, granting them exclusive marketing rights and commercialization responsibilities. Additionally, 3SBio will entrust Hybio with the exclusive production and supply of the semaglutide product for weight loss indication.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3387#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=3387\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3387#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical - Insight, China's Pharmaceutical Industry","description":"3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced a licensing agreement with fellow Chinese firm Hybio Pharmaceutical Co., Ltd (SHE: 300199) for the development of a semaglutide biosimilar. Under this agreement, 3SBio will gain access to Hybio's preclinical technical results for the drug and will be responsible for clinical research and registration application work. This will enable 3SBio to become the marketing authorization holder (MAH) for the semaglutide product, indicated for weight loss, in a specific region, granting them exclusive marketing rights and commercialization responsibilities. Additionally, 3SBio will entrust Hybio with the exclusive production and supply of the semaglutide product for weight loss indication.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=3387","og_locale":"en_US","og_type":"article","og_title":"3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=3387","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-05-29T01:15:24+00:00","article_modified_time":"2024-10-20T09:58:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=3387#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=3387"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical","datePublished":"2024-05-29T01:15:24+00:00","dateModified":"2024-10-20T09:58:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=3387"},"wordCount":207,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["3SBio","Biosimilars","HKG: 1530","Huadong Medicine","Hybio Pharmaceutical","Livzon Pharmaceutical","Novo Nordisk","Obesity","SHE: 300199"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=3387#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=3387","url":"https:\/\/flcube.com\/?p=3387","name":"3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-05-29T01:15:24+00:00","dateModified":"2024-10-20T09:58:49+00:00","description":"3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced a licensing agreement with fellow Chinese firm Hybio Pharmaceutical Co., Ltd (SHE: 300199) for the development of a semaglutide biosimilar. Under this agreement, 3SBio will gain access to Hybio's preclinical technical results for the drug and will be responsible for clinical research and registration application work. This will enable 3SBio to become the marketing authorization holder (MAH) for the semaglutide product, indicated for weight loss, in a specific region, granting them exclusive marketing rights and commercialization responsibilities. Additionally, 3SBio will entrust Hybio with the exclusive production and supply of the semaglutide product for weight loss indication.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=3387#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=3387"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=3387#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/3387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3387"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/3387\/revisions"}],"predecessor-version":[{"id":8185,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/3387\/revisions\/8185"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}